Ranbaxy Presents Corrective Plans To U.S. FDA
This article was originally published in PharmAsia News
Ranbaxy Laboratories of India has presented U.S. FDA a "corrective action" plan to satisfy the agency's complaints about some of the drugs exported to the United States from certain Ranbaxy plants. An FDA spokesman agreed the agency and Ranbaxy are working to clear the problems raised by the FDA. Ranbaxy's new CEO, appointed by Japan's Daiichi Sankyo after buying Ranbaxy, said he expects the problems to be cleared and Ranbaxy given full FDA approval in a few months. (Click here for more
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Commissioner Hahn’s tweet announcing a return to inspections, while not a new policy, may be signal that FDA understands sponsor concerns with the agency’s limited ability to conduct onsite inspections. Effort may be aimed at reassuring industry even as CRLs related to manufacturing increase.
Rushed final rule seeking to impose draconian cuts on drug reimbursement rates in the Medicare Part B program is certain to face legal and political obstacles. But the data included on international price benchmarks will still have an impact.